1. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Issue 9 (September 2019) Authors: Grinsztejn, Beatriz; Hughes, Michael D; Ritz, Justin; Salata, Robert; Mugyenyi, Peter; Hogg, Evelyn; Wieclaw, Linda; Gross, Robert; Godfrey, Catherine; Cardoso, Sandra W; Bukuru, Aggrey; Makanga, Mumbi; Faesen, Sharlaa; Mave, Vidya; Wangari Ndege, Beatrice; Nerette Fontain, Sandy; Samaneka, Wadza... Journal: Lancet Issue: Volume 6:Issue 9(2019) Page Start: e588 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial. Issue 6 (15th June 2022) Authors: Avihingsanon, Anchalee; Hughes, Michael D.; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn; Mugyenyi, Peter; Hogg, Evelyn; Gross, Robert; Cardoso, Sandra W.; Bukuru, Aggrey; Makanga, Mumbi; Badal‐aesen, Sharlaa; Mave, Vidya; Ndege, Beatrice Wangari; Fontain, Sandy Nerette; Samaneka, Wadzan... Journal: Journal of the International AIDS Society Issue: Volume 25:Issue 6(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗